ACLX-002 is under clinical development by Arcellx and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACLX-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACLX-002 overview
ACLX-002 is under development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The immune cell therapy is composed of a combination of antigen receptor complex T cells (ARC-T) and monovalent SparX proteins, SPRX002 that kills the tumor cells. It acts by targeting cells expressing CD123 and is administered through parenteral route. The drug candidate is being developed based on ARC-SparX platform.
Arcellx overview
Arcellx is a clinical-stage biopharmaceutical company that develops, manufactures and markets adaptive cell therapies for treatment of cancer, acute myeloid leukemia, solid tumors and autoimmune diseases. It is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of ACLX-002’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
